- Available Technology
Miyocardial therapy, Cardiotoxicity, Drug therapy, In vitro screening, Biomedical
The myocardial in vitro screening platform is a bioreactor system providing a physiologically relevant environment through precise control of the dynamic force-length relationship that occurs in the myocardial tissue constructs. This precise control recapitulates the pressure-volume mechanical relationships found in the native myocardium that are often evaluated in the progression or diagnosis of cardiac pathologies. The platform not only simulates this environment but also produces physiologically relevant metrics such as tissue stiffness, contractility, stroke work, and cardiac output curves which directly translate to clinically relevant treatment metrics. The nature of the technology platform is conducive for high-throughput therapy screening, in vitro research acceleration, cardiotoxicity assessment, and long-term personalized patient diagnostics and therapy selection.
TRL4: Research Prototype
William Richardson, Samuel Coeyman, Jonathan G. Heywood
Technology Commercialization Officer
Stay up-to-date with the latest trends in the innovation and research industry. Sign up for our newsletter to see how CURF is making a difference and impacting the economy where we live.